Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPICAL-1: Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC
NCT06822543Phase 2Recruiting
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- Sep 2025
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Latin American Cooperative Oncology Group. Primary endpoint: Intracranial Objective Response Rate at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT06822543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822543.